DK1824504T3 - Anti-tumor-kombinationer, der indeholder VEGF-trap og 5-fluoruracil eller et derivat deraf - Google Patents

Anti-tumor-kombinationer, der indeholder VEGF-trap og 5-fluoruracil eller et derivat deraf

Info

Publication number
DK1824504T3
DK1824504T3 DK05824581T DK05824581T DK1824504T3 DK 1824504 T3 DK1824504 T3 DK 1824504T3 DK 05824581 T DK05824581 T DK 05824581T DK 05824581 T DK05824581 T DK 05824581T DK 1824504 T3 DK1824504 T3 DK 1824504T3
Authority
DK
Denmark
Prior art keywords
fluorouracil
derivative
vegf trap
combinations containing
containing vegf
Prior art date
Application number
DK05824581T
Other languages
Danish (da)
English (en)
Inventor
Eric Furfine
Jocelyn Holash
Jesse M Cedarbaum
Patricia Vrignaud
Marielle Chiron-Blondel
Marie-Christine Bissery
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34954452&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1824504(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of DK1824504T3 publication Critical patent/DK1824504T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK05824581T 2004-12-03 2005-12-02 Anti-tumor-kombinationer, der indeholder VEGF-trap og 5-fluoruracil eller et derivat deraf DK1824504T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0412870A FR2878749B1 (fr) 2004-12-03 2004-12-03 Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
PCT/FR2005/003005 WO2006059012A1 (fr) 2004-12-03 2005-12-02 Combinaisons antitumorales contenant un agent inhibiteur de vegf et du 5fu ou un de ses derives

Publications (1)

Publication Number Publication Date
DK1824504T3 true DK1824504T3 (da) 2009-07-20

Family

ID=34954452

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05824581T DK1824504T3 (da) 2004-12-03 2005-12-02 Anti-tumor-kombinationer, der indeholder VEGF-trap og 5-fluoruracil eller et derivat deraf

Country Status (25)

Country Link
US (3) US20060178305A1 (enExample)
EP (1) EP1824504B1 (enExample)
JP (1) JP4980236B2 (enExample)
KR (1) KR101313404B1 (enExample)
CN (1) CN101068564B (enExample)
AT (1) ATE426409T1 (enExample)
AU (1) AU2005311191C1 (enExample)
BR (1) BRPI0518700B8 (enExample)
CA (1) CA2586735C (enExample)
CY (3) CY1109181T1 (enExample)
DE (1) DE602005013568D1 (enExample)
DK (1) DK1824504T3 (enExample)
ES (1) ES2324233T3 (enExample)
FR (3) FR2878749B1 (enExample)
HR (1) HRP20090336T1 (enExample)
IL (1) IL183481A (enExample)
LU (2) LU92202I2 (enExample)
ME (1) ME01706B (enExample)
MX (1) MX2007006607A (enExample)
PL (1) PL1824504T3 (enExample)
PT (1) PT1824504E (enExample)
RS (1) RS50769B (enExample)
RU (1) RU2384344C2 (enExample)
SI (1) SI1824504T1 (enExample)
WO (1) WO2006059012A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
RS58957B1 (sr) 2014-07-18 2019-08-30 Sanofi Sa Postupak za predviđanje ishoda tretmana sa afliberceptom kod pacijenta za kog se sumnja da boluje od raka
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
EP3246029A1 (en) * 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN115197948A (zh) * 2021-04-13 2022-10-18 江苏康缘瑞翱生物医药科技有限公司 一种重组新城疫病毒rNDV-VEGF-Trap、其基因组、制备方法及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU9701081D0 (en) * 1997-06-23 1997-08-28 Gene Research Lab Inc N Pharmaceutical composition of antitumoral activity
CN101433715B (zh) * 1999-06-08 2013-04-17 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo

Also Published As

Publication number Publication date
SI1824504T1 (sl) 2009-08-31
MX2007006607A (es) 2007-07-25
KR101313404B1 (ko) 2013-10-01
ATE426409T1 (de) 2009-04-15
AU2005311191C1 (en) 2015-04-30
LU92203I2 (fr) 2013-11-15
PL1824504T3 (pl) 2009-08-31
US20060178305A1 (en) 2006-08-10
HK1114769A1 (en) 2008-11-14
AU2005311191A1 (en) 2006-06-08
CY2013018I1 (el) 2020-05-29
AU2005311191B2 (en) 2011-12-08
CN101068564A (zh) 2007-11-07
CA2586735C (fr) 2014-08-12
FR13C0025I1 (fr) 2013-05-24
LU92203I9 (enExample) 2019-01-15
WO2006059012A1 (fr) 2006-06-08
EP1824504A1 (fr) 2007-08-29
DE602005013568D1 (de) 2009-05-07
LU92202I9 (enExample) 2019-01-15
FR13C0024I1 (fr) 2013-05-24
ES2324233T3 (es) 2009-08-03
BRPI0518700B1 (pt) 2020-02-11
RS50769B (sr) 2010-08-31
FR2878749A1 (fr) 2006-06-09
CN101068564B (zh) 2010-12-15
IL183481A0 (en) 2007-09-20
US8388963B2 (en) 2013-03-05
BRPI0518700A2 (pt) 2008-12-02
KR20070091130A (ko) 2007-09-07
CY2013017I1 (el) 2014-07-02
CY1109181T1 (el) 2014-07-02
EP1824504B1 (fr) 2009-03-25
ME01706B (me) 2010-08-31
US20090285841A1 (en) 2009-11-19
LU92202I2 (fr) 2013-11-15
CA2586735A1 (fr) 2006-06-08
RU2007123607A (ru) 2009-01-10
HRP20090336T1 (hr) 2009-07-31
JP4980236B2 (ja) 2012-07-18
PT1824504E (pt) 2009-06-25
IL183481A (en) 2013-09-30
FR2878749B1 (fr) 2007-12-21
US20130184205A1 (en) 2013-07-18
RU2384344C2 (ru) 2010-03-20
BRPI0518700B8 (pt) 2021-05-25
JP2008521866A (ja) 2008-06-26

Similar Documents

Publication Publication Date Title
LU92202I2 (fr) Aflibercept
CL2022003733A1 (es) Análogos de nucleósido de 1’-ciano y usos de los mismos
CY1119810T1 (el) Παραγωγα(2s,3r,4r,5s,6r)-2-(4-χλωρο-3-βενζυλφαινυλ)-6-(υδροξυμεθυλ)τετραϋδρο-2h-πυραν-3,4,5-τριολης για χρηση στη θεραπεια του διαβητη
CY1107440T1 (el) Ενωσεις αρυλουριας εν συνδυασμω με αλλα κυτταροστατικα ή κυτταροτοξικα μεσα για τη θεραπεια ανθρωπινων καρκινων
JOP20220020B1 (ar) مثبطات kars تعتمد على akr1c3 ثلاثية الحلقة
CL2007001996A1 (es) Compuestos derivados de heteroarilos nitrogenados sustituidos con fenilo, inhibidores de la produccion de citoquinas; composicion farmaceutica que los comprende; y sus usos en el tratamiento del cancer, infecciones, enfermedades inflamatorias y autoinmunes.
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
CY1113166T1 (el) Αναστολεις των ενζυμων ενεργοποιησης ε1
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
CY1111121T1 (el) Ετεροαρυλο ενωσεις χρησιμες ως αναστολεις ενζυμων ενεργοποiησης ε1
UY31314A1 (es) Amidas heterociclicas y sus métodos de uso-976
CY1112383T1 (el) Αναστολεις της πρωτεϊνης ενεργοποιησης της 5-λιποξυγενασης (flap)
NO20060424L (no) 5-heteroringbaserte P38 kinaseinhibitorer
DK1824489T3 (da) Stereoisomerisk berigede 3-arminocarbonyl-bicyclohepten-pyrimidinamin-forbindelser og anvendelse deraf
NO20062420L (no) Anvendelse av IAP-oligomer og et kjemoterapeutisk middel for behandling av proliferative sykdommer
ATE489371T1 (de) Benzamidglucokinaseaktivatoren
NO20070580L (no) Behandling av cancer.
CL2007001748A1 (es) Compuesto derivado de 2-arilamino-4-aminopirimidinas, inhibidores de la proteina quinasa c-alfa; composiciones farmaceuticas que los contienen; y su uso para tratar o prevenir la diabetes, el cancer, enfermedades cardiovasculares y otras.
JOP20220315A1 (ar) جزيئات ربط لعلاج السرطان
ATE499098T1 (de) Verwendung von parp-1-hemmern
NO20076663L (no) Immunoglobuliner
SE0300457D0 (sv) Novel compounds
EA200971103A1 (ru) Иммуноцитокины для лечения рака в сочетании с химиотерапевтическими агентами
DK1605963T3 (da) Hæmmere af antigenpræsentation med MHC-klasse-II-molekyler og fremgangsmåder til anvendelse deraf
DE602005010844D1 (de) Pharmazeutische zusammensetzungen mit interferon-tau